Regeneron shares attractive at current levels, says Citigroup Citigroup expects sales of Eylea to rebound in Q2 and it finds shares of Regeneron attractive at current levels. Citi says the stock has been weak over the past two weeks amid concerns that use of Avastin will grow. After surveying 31 retinal specialists, Citi keeps a Buy rating on Regeneron with a $390 price target.
News For REGN From The Last 14 Days
Check below for free stories on REGN the last two weeks.